Drug intelligence / Profile preview

SGR-8139

Development stage: Preclinical
Lead developer: Schrödinger
Modality: Small Molecules
Administration: Oral

Overview

SGR-8139 is a preclinical-stage, orally bioavailable small molecule drug candidate developed by Schrodinger. It is being investigated for the treatment of inflammatory and immunological diseases. The compound was identified using Schrodinger's physics-based computational platform and is designed to modulate a specific cytokine target. Detailed information regarding the specific cytokine or the exact mechanism of action has not been publicly disclosed by the developer, as it remains in the early stages of internal development.

Beyond the preview

Go deeper on SGR-8139.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGR-8139.

Explore the full profile